ASH 2020: Bispecifics Battle For Share Of BCMA Market In Myeloma
CAR-T Therapies Will Beat T-Cell Engagers To Market
Executive Summary
Response rates for multiple myeloma patients treated with BCMA-targeting bispecific antibodies are lower than for CAR-T therapies, but adverse event rates are lower for the off-the-shelf treatments.
You may also be interested in...
J&J Adds Second Anti-BCMA Myeloma Therapy In US With Tecvayli Approval
Johnson & Johnson’s Janssen Pharmaceutical is building a multiple myeloma franchise beyond Darzalex, now with two BCMA-targeting therapies after CAR-T therapy Carvykti’s February approval.
Approval Delayed, But Janssen/Legend’s Cilta-Cel May Hit Market Just In Time
The US FDA has extended the user fee date by three months for the partners’ BCMA-targeting CAR-T therapy but its first-to-market rival is facing manufacturing challenges that limit access to treatment.
Amgen Builds Out Antibody Interests With $2.5bn Teneobio Buy
Private California venture will bring additional expertise and novel platforms to acquisitive biotech giant as it looks to expand its interests in bispecific and multispecific antibody technologies.